Annexon Biosciences is looking to map out a path forward for ANX007 in geographic atrophy (GA) after a Phase II study failed to meet the primary endpoint typically used for US Food and Drug Administration approval, based on an improvement in visual function. But it’s a space where Apellis Pharmaceuticals, Inc.’s Syfovre (pegcetacoplan) has already won approval, and Iveric Bio’s Zimura (avacincaptad pegol) is undergoing FDA review, with a decision anticipated in the coming months.
Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward
The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.
